Oxford BioDynamicsOXBOF Return-on-Tangible-Equity is -502.41% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 95.31% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Oxford BioDynamics's annualized net income for the quarter that ended in Sep. 2025 was $-14.60 Mil. Oxford BioDynamics's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $2.91 Mil. Therefore, Oxford BioDynamics's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was -502.41%.
The historical rank and industry rank for Oxford BioDynamics's Return-on-Tangible-Equity or its related term are showing as below:
OXBOF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -739.34 Med: -57.27 Max: -12.5
Current: -445.82
During the past 13 years, Oxford BioDynamics's highest Return-on-Tangible-Equity was -12.50%. The lowest was -739.34%. And the median was -57.27%.
OXBOF's Return-on-Tangible-Equity is ranked worse than 95.31% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs OXBOF: -445.82
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Oxford BioDynamics Return-on-Tangible-Equity Related Terms
Oxford BioDynamics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXBOF vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -502.41% mean?
Oxford BioDynamics (OXBOF) has a Return-on-Tangible-Equity of -502.41% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #183 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 95.3%.
Is Oxford BioDynamics' Return-on-Tangible-Equity too high?
Oxford BioDynamics' current Return-on-Tangible-Equity is -502.41%. Based on the distribution chart, Oxford BioDynamics ranks #183 out of 192 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #183 out of 192 companies for Return-on-Tangible-Equity. This places Oxford BioDynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Return-on-Tangible-Equity is -502.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.00 — trading 96.7% below its estimated fair value. The current Return-on-Tangible-Equity is -502.41%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Return-on-Tangible-Equity is -502.41% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBOF has been successfully added to your 